We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?
Read MoreHide Full Article
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.
Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large.
Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. For example, value investors will be interested in stocks with great grades in the "Value" category. When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today.
Collegium Pharmaceutical (COLL - Free Report) is a stock many investors are watching right now. COLL is currently holding a Zacks Rank of #2 (Buy) and a Value grade of A.
Value investors also frequently use the P/S ratio. This metric is found by dividing a stock's price with the company's revenue. This is a prefered metric because revenue can't really be manipulated, so sales are often a truer performance indicator. COLL has a P/S ratio of 1.69. This compares to its industry's average P/S of 3.29.
Finally, investors will want to recognize that COLL has a P/CF ratio of 5.51. This metric takes into account a company's operating cash flow and can be used to find stocks that are undervalued based on their solid cash outlook. This stock's P/CF looks attractive against its industry's average P/CF of 10.45. Within the past 12 months, COLL's P/CF has been as high as 8.61 and as low as 5.26, with a median of 6.44.
Another great Medical - Drugs stock you could consider is Jazz Pharmaceuticals (JAZZ - Free Report) , which is a # 2 (Buy) stock with a Value Score of A.
Jazz Pharmaceuticals is trading at a forward earnings multiple of 5.87 at the moment, with a PEG ratio of 0.84. This compares to its industry's average P/E of 58.22 and average PEG ratio of 2.36.
JAZZ's Forward P/E has been as high as 6.87 and as low as 4.97, with a median of 5.62. During the same time period, its PEG ratio has been as high as 1.44, as low as 0.64, with a median of 1.07.
Jazz Pharmaceuticals sports a P/B ratio of 1.88 as well; this compares to its industry's price-to-book ratio of 1.35. In the past 52 weeks, JAZZ's P/B has been as high as 2.27, as low as 1.59, with a median of 1.89.
These are only a few of the key metrics included in Collegium Pharmaceutical and Jazz Pharmaceuticals strong Value grade, but they help show that the stocks are likely undervalued right now. When factoring in the strength of its earnings outlook, COLL and JAZZ look like an impressive value stock at the moment.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.
Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large.
Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. For example, value investors will be interested in stocks with great grades in the "Value" category. When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today.
Collegium Pharmaceutical (COLL - Free Report) is a stock many investors are watching right now. COLL is currently holding a Zacks Rank of #2 (Buy) and a Value grade of A.
Value investors also frequently use the P/S ratio. This metric is found by dividing a stock's price with the company's revenue. This is a prefered metric because revenue can't really be manipulated, so sales are often a truer performance indicator. COLL has a P/S ratio of 1.69. This compares to its industry's average P/S of 3.29.
Finally, investors will want to recognize that COLL has a P/CF ratio of 5.51. This metric takes into account a company's operating cash flow and can be used to find stocks that are undervalued based on their solid cash outlook. This stock's P/CF looks attractive against its industry's average P/CF of 10.45. Within the past 12 months, COLL's P/CF has been as high as 8.61 and as low as 5.26, with a median of 6.44.
Another great Medical - Drugs stock you could consider is Jazz Pharmaceuticals (JAZZ - Free Report) , which is a # 2 (Buy) stock with a Value Score of A.
Jazz Pharmaceuticals is trading at a forward earnings multiple of 5.87 at the moment, with a PEG ratio of 0.84. This compares to its industry's average P/E of 58.22 and average PEG ratio of 2.36.
JAZZ's Forward P/E has been as high as 6.87 and as low as 4.97, with a median of 5.62. During the same time period, its PEG ratio has been as high as 1.44, as low as 0.64, with a median of 1.07.
Jazz Pharmaceuticals sports a P/B ratio of 1.88 as well; this compares to its industry's price-to-book ratio of 1.35. In the past 52 weeks, JAZZ's P/B has been as high as 2.27, as low as 1.59, with a median of 1.89.
These are only a few of the key metrics included in Collegium Pharmaceutical and Jazz Pharmaceuticals strong Value grade, but they help show that the stocks are likely undervalued right now. When factoring in the strength of its earnings outlook, COLL and JAZZ look like an impressive value stock at the moment.